https://www.live-feeds.com/feed/astrazeneca-buys-partner-omniose-for-bacterial-vaccine-technologyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/astrazeneca-buys-partner-omniose-for-bacterial-vaccine-technologyhttps://www.live-feeds.com/feed/astrazeneca-buys-partner-omniose-for-bacterial-vaccine-technology#u200458Sat, 14 Nov 2026 11:50:36 +0000Pharmaceutical giant AstraZeneca has acquired its partner Omniose to secure bacterial vaccine technology. The transaction strengthens AstraZeneca's vaccine pipeline by integrating the startup's platform, which provides a simpler method for manufacturing conjugate vaccines. This buyout builds on an existing relationship between the two companies, transitioning Omniose from a partner to a wholly owned subsidiary. Industry observers note that the acquisition expands AstraZeneca's technical capabilities in combating bacterial infections.Why it mattersThe acquisition expands AstraZen